Cyclosporin

ApprovedSmall molecule

AstraZeneca

Cyclosporin is one of 370 small molecule programs targeting Liver Transplant. It is currently in Approved.

Indications

Total Trials

Active Trials

369

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

IschemiaActive, not recruiting

LymphomaActive, not recruiting

Eye DiseaseActive, not recruiting

HistiocytosisActive, not recruiting

Kidney TransplantActive, not recruiting

Membranoproliferative GlomerulonephritisActive, not recruiting

Bone Marrow TransplantationActive, not recruiting

PsoriasisActive, not recruiting

Alopecia AreataActive, not recruiting

Liver TransplantApproved

Active, not recruiting

IschemiaPreclinical

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Eye DiseasePhase 2

Active, not recruiting

HistiocytosisPhase 3

Active, not recruiting

Kidney TransplantApproved

Active, not recruiting

Membranoproliferative GlomerulonephritisPhase 3

Active, not recruiting

Bone Marrow TransplantationPhase 1

Active, not recruiting

PsoriasisPhase 1

Active, not recruiting

Alopecia AreataApproved

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Cyclosporin

AstraZeneca

Approved

1 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Norvir

AbbVie

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

PEG-Intron

Merck & Co.

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

2 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Recruiting

Membranous Nephropathy

NCT06470191

Q4 2027

Post-ApprovalRecruiting

Alopecia Areata

NCT07381556

Q2 2028

Phase 2Recruiting

Type 1 Diabetes

NCT05153070

Q1 2029

Phase 2Not yet recruiting

Membranous Nephropathy

NCT07029139

Clinical

Trials by Indication[1]

Membranous Nephropathy2 trials

A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2·NCT07029139·156 enrolled

A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.

Recruiting·SShanghai Jiaolian Drug Research and Development Co., Ltd·Phase 2/3·NCT06470191·216 enrolled

Sjögren Syndrome1 trial

Effect of Ciclosporin Eyedrops on Sjögren Syndrome

Completed·HHospital Hietzing·N/A·NCT04597762·12 enrolled

Histiocytosis1 trial

Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004

Completed·KKarolinska University Hospital·Phase 3·NCT00426101·368 enrolled

Alopecia Areata1 trial

Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study

Recruiting·EErasmus Medical Center·Phase 4·NCT07381556·50 enrolled

Psoriasis1 trial

Combined Use of Cyclosporine and Metformin in Treatment of Psoriasis vs Cyclosporine Alone

Completed·—·Phase 1·NCT07375654·32 enrolled

12 more indications

Eye Disease1 trial

Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease

Terminated·UUniversity of Missouri-Columbia·Phase 2·NCT01072526·7 enrolled

Liver Transplant1 trial

Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

Completed· Novartis logo

Novartis·Phase 4·NCT00938860·92 enrolled

Lymphoma1 trial

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

Terminated·EEastern Cooperative Oncology Group·Phase 2·NCT00057954·6 enrolled

Membranoproliferative Glomerulonephritis1 trial

Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis

Unknown status·—·Phase 3·NCT03180723·30 enrolled

Bone Marrow Transplantation1 trial

Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00705120·9 enrolled

Ischemia1 trial

Effect of Cyclosporine and Remote Ischemic Preconditioning in Reperfusion Ischemia Injury on Tetralogy Fallot Patients With Correction Surgery

Completed·IIndonesia University·N/A·NCT05691764·40 enrolled

Completed·SStanford University·Phase 4·NCT00296296·29 enrolled

Type 1 Diabetes1 trial

Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05153070·24 enrolled

Tacrolimus1 trial

Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04788641·62 enrolled

Dry Eye Disease (DED)1 trial

A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study

Completed·LLaboratoires Thea··NCT07234318·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Cyclosporin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyclosporin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyclosporin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AstraZeneca

Cyclosporin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q2 2028

Q1 2029

Trials by Indication[1]

Membranous Nephropathy2 trials

Sjögren Syndrome1 trial

Histiocytosis1 trial

Alopecia Areata1 trial

Psoriasis1 trial

Eye Disease1 trial

Liver Transplant1 trial

Lymphoma1 trial

Membranoproliferative Glomerulonephritis1 trial

Bone Marrow Transplantation1 trial

Ischemia1 trial

Focal Segmental Glomerulosclerosis1 trial

Stem Cell Transplantation1 trial

Kidney Transplant1 trial

Type 1 Diabetes1 trial

Tacrolimus1 trial

Dry Eye Disease (DED)1 trial

References

Drug Info

Quick Facts

Related News